A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 100, Issue 1, 2006, Pages 111-115

  Chen, M Dwight ^a   Fleming, Gini F ^b   Mitchell, Suann ^c   Horowitz, Ira ^d  

^a Center for Gynecologic Oncology and Pelvic Surgery   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Gemcitabine; Recurrent ovarian cancer; Refractory; Topotecan

Indexed keywords

CAMPTOTHECIN; CARBOPLATIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM; TOPOTECAN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DRUG DOSE REGIMEN; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LUNG TOXICITY; MAXIMUM TOLERATED DOSE; OVARY CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; STOMATITIS; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TOPOTECAN;

EID: 29144450350     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.07.114     Document Type: Article

References (24)

1. A. Jemal, R. Tiwari, T. Murray, A. Ghafoor, A. Samuels, and E. Ward Cancer statistics, 2004 CA J. Cancer Clin. 54 2004 8 29
2. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer N. Engl. J. Med. 334 1996 1 6
3. R.C. Gallo, J. Whang-Peng, and R.H. Adamson Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin J. Natl. Cancer Inst. 46 1971 789 795
4. E. Rowinsky, L. Grochow, and C. Hendricks Phase I and pharmacologic study of topotecan (SK and F 104864): a novel topoisomerase inhibitor J. Clin. Oncol. 10 1992 647 656
5. A.Y. Chen, and A.F. Liu DNA topoisomerases: essential enzymes and lethal targets Annu. Rev. Pharmacol. Toxicol. 34 1994 191 218
6. W. ten Bokkel Huinink, M. Gore, and J. Carmichael Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer J. Clin. Oncol. 15 1997 2183 2193
7. D.C. DeLong, L.W. Hertel, and J. Tang Antiviral activity of 2′, 2′ difluorodeoxycitidine Abstracts of the Annual Meeting of the American Society for Microbiology, Washington D.C., March 24-28 1995
8. P. Huang, and W. Plunkett Induction of apoptosis by gemcitabine Semin. Oncol. 22 Suppl 11 1995 19 25
9. L.W. Hertel, G.B. Boder, and J.S. Kroin Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′deoxycytidine) Cancer Res. 50 1990 4417 4422
10. J.D. Shapiro, M.J. Millward, and D. Rischin Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel Gynecol. Oncol. 63 1996 89 93
11. B. Lund, O.P. Hansen, and J.P. Neijt Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients Anticancer Drugs 6 Suppl 6 1995 61 62
12. M.R. Green Gemcitabine safety overview Semin Oncol. 23 Suppl 10 1996 32 35
13. K. Seiter, E.J. Feldman, and D. Halicka Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia J. Clin. Oncol. 15 1997 44 51
14. P. Pourquier, C. Gioffre, and G. Kohlhagen Gemcitabine (2′,2′-difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase I Clin. Cancer Res. 8 2002 2499 2504
15. M. Distefano, C. Ferlini, and R. De Vincenzo Antagonistic effect of the combination gemcitabine/topotecan in ovarian cancer cells Oncol. Res. 12 2000 355 359
16. S. Greggi, M.G. Salerno, and G. D'Agostino Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer Oncology 60 2001 19 23
17. D. Rinaldi, N. Lormand, and J. Brierre A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3) Cancer Invest. 19 2001 467 474
18. W. Sun, J.P. Stevenson, and M. Gallagher A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors Cancer 92 2001 414 419
19. M.J. Guarino, C.J. Schneider, and S.S. Grubbs A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer Oncologist 7 2002 509 515
20. J. Sehouli, D. Stengel, G. Oskay, J. Blohmer, S. Kaubitzsch, and W. Lichtenegger A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum J. Obstet. Gynaecol. Res. 29 2003 123 131
21. M.G. Joppert, D.H. Garfield, and M.A. Gregurich A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer Lung Cancer 39 2003 215 219
22. M.B. Dabrow, M.R. Francesco, P.B. Gilman, R. Cantor, L. Rose, and T.J. Meyer Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer Cancer Invest. 21 2003 512 517
23. R.T. Morris Weekly topotecan in the management of ovarian cancer Gynecol. Oncol. 90 2003 S34 S38
24. D.F. Roychowdhury, C.A. Cassidy, P. Peterson, and M. Arning A report on serious pulmonary toxicity associated with gemcitabine-based therapy Invest. New Drugs 20 3 2002 311 315